76 Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011;117(12):2637-42. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502-1510. Palsdottir HB, Hardarson S, Petursdottir V, et al. Incidental detection of renal cell carcinoma is an independent prognostic marker: results of a long-term, whole population study. J Urol. 2012;187(1):48-53. Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797. Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659. Jubb AM, Cesario A, Ferguson M, Congedo MT, Gatter KC, Lococo F et al. Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. British Journal of Cancer volume 104, pages 1877–1881 (07 June 2011) Zettter. The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer. 2008 Aug;8(8):647-54. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer, version 3.2019, February 6, 2018. Disponible en: http://www.nccn.org B. Escudier, C. Porta, M. Schmidinger, N. Rioux-Leclercq, A. Bex, V. Khoo, V. Grünwald, S. Gillessen and A. Horwich. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. Mar 2009;45(5):765-773. Gallardo, E., Méndez-Vidal, M. J., Pérez-Gracia, J. L., Sepúlveda-Sánchez, J. M., Campayo, M., Chirivella- González, I., García-Del-Muro, X., González-Del-Alba, A., Grande, E., … Suárez, C. (2017). SEOM clinical guideline for treatment of kidney cancer (2017). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 20(1), 47-56. García Del Muro X, Gallardo E, García Carbonero I, Laínez N, José Méndez M, Maroto P, et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Jun;73(6):1095-107 Ljungberg B, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.02.011. Cabometyx®. EPAR CHMP 2016. http://www.ema.europa.eu/ema/ Ficha técnica Cabometyx 2019. Zhou L, Wang XL, Deng QL, Du YQ, Zhao NQ. The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. Nature Scientific Reports. 2016a;6:32020. DOI : 10.1038/srep32020. Yu H, Liu R, Ma B, Li X, Yen HY, Zhou Y, et al. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer. 2015;113(4):616-25. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee J L, Peltola K, et al; METEOR Investigators.: Cabozantinib versus everolimus in advanced renal cell carcinoma.N Engl J Med. 2015;373: 1814- 1823. Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-27. Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff KM, Aftab DT, et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res. 2014;20(3):617-30. Graham TJ, Box G, Tunariu N, Crespo M, Spinks TJ, Miranda S, et al. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst. 2014;106(4):dju033. doi: 10.1093/jnci/dju033. Epub 2014 Mar 14. Nguyen HM, et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One. 2013;8(10):e78881.Erratum in PLoS One. 2014;9(8):e106797. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660-6.